How should thrombotic microangiopathy be initially managed?

Initial Management of Thrombotic Microangiopathy

Initiate plasma exchange therapy within 4-8 hours of presentation for suspected TMA, while simultaneously obtaining pre-treatment blood samples for ADAMTS13 activity and complement studies 1, 2.

Immediate Diagnostic Confirmation (First 1-2 Hours)

The syndromic diagnosis requires confirming microangiopathic hemolytic anemia (MAHA) and thrombocytopenia (MAHAT):

• Elevated: LDH, indirect bilirubin, reticulocytes
• Present: Schistocytes on peripheral blood smear
• Negative: Direct Coombs test
• Low: Platelet count with thrombocytopenia

These findings not explained by other secondary causes confirm TMA 1.

Critical Pre-Treatment Blood Sampling

Before any plasma therapy is administered, obtain:

• Sodium citrate plasma sample for ADAMTS13 activity - this is non-negotiable as plasma exchange will invalidate the test 2
• Complement studies (C3, C4, factor H, factor I, MCP)
• Complete blood count, peripheral smear
• Renal function, LDH, haptoglobin, indirect bilirubin

Emergent Treatment Algorithm

Step 1: Immediate ICU Admission

All patients with confirmed MAHAT require intensive care unit admission for close monitoring and treatment initiation 1.

Step 2: Empirical Plasma Exchange (Within 4-8 Hours)

Start plasma exchange immediately in all adults with suspected TMA, treating empirically as thrombotic thrombocytopenic purpura (TTP) until proven otherwise 1, 2. This approach is critical because:

• TTP can cause precipitous, irreversible, and fatal organ failure 2
• Mortality is significantly reduced with early plasma exchange
• Waiting for ADAMTS13 results delays life-saving therapy

The evidence strongly supports this aggressive approach, with multiple consensus guidelines emphasizing the 4-8 hour window 1, 2.

Step 3: Age-Specific Considerations

In children: Do NOT start plasma exchange empirically. First exclude Shiga toxin-associated HUS (STEC-HUS) as this is the most common pediatric TMA and is managed supportively, not with plasma exchange 2. Check stool for Shiga toxin-producing E. coli.

In adults: Proceed directly to plasma exchange as outlined above.

Subsequent Management Based on Etiology

If ADAMTS13 Activity <10%:

• Continue daily plasma exchange for TTP
• Consider rituximab for acquired TTP with inhibitors
• Caplacizumab may be added in severe cases (though not mentioned in provided guidelines)

If ADAMTS13 Activity Normal and Complement Abnormalities Present:

• Transition to eculizumab (complement C5 inhibitor) for atypical HUS (aHUS) 2
• Continue supportive care
• Genetic testing reveals complement mutations in a significant proportion of aHUS cases 2, 3

If Secondary TMA Identified:

• Address underlying cause (infection, malignancy, drugs, pregnancy)
• However, do not assume secondary causes exclude complement-mediated disease - many secondary TMAs harbor unrecognized complement abnormalities 3
• Consider complement inhibition even in secondary TMA if kidney function deteriorates, as 60% show improvement at 6 months 3

Critical Pitfalls to Avoid

1. Delaying plasma exchange while awaiting test results - this increases mortality in TTP 1, 2
2. Giving plasma products before obtaining ADAMTS13 sample - invalidates the diagnostic test 2
3. Assuming secondary causes exclude complement-mediated TMA - these often coexist and complement inhibition may still benefit 3
4. Starting plasma exchange in children before excluding STEC-HUS - unnecessary intervention with risks 2
5. In pregnancy-associated TMA: Check sFlt1/PlGF ratio to differentiate pre-eclampsia (high ratio) from complement-mediated TMA (low ratio), as treatment differs fundamentally 4

Monitoring and Supportive Care

• Daily platelet counts, LDH, hemoglobin
• Renal function monitoring
• Neurological assessments
• Blood pressure control (especially important as renal TMA is present in 95% of malignant hypertension cases) 5

The evidence consistently demonstrates that time to plasma exchange is the most critical determinant of outcomes in TMA, with the 4-8 hour window representing the standard of care for adult patients 1, 2. This aggressive approach prioritizes mortality reduction over diagnostic certainty, which can be refined as test results return.